• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
HTX
Click for more information
0.00% 0.1¢

HEALTHLINX LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
BEZ +Suspension from Official Quotation - Annual Listing FeePRICE SENSITIVE25/08/14
HTX Market Update and Capital RaisingPRICE SENSITIVE13/06/14
HTXSuspension from Official QuotationPRICE SENSITIVE30/04/13
HTXMutual Termination of La Jolla Cove Investors Inc FacilityPRICE SENSITIVE18/03/13
HTXHalf Yearly Report and AccountsPRICE SENSITIVE28/02/13
HTXAppendix 4C - quarterlyPRICE SENSITIVE31/01/13
HTXHOA with Mane Cancer Diagnostic ExpiresPRICE SENSITIVE31/12/12
HTXChairman's Address to ShareholdersPRICE SENSITIVE28/11/12
HTXPrimary objective achieved in second OvPlex studyPRICE SENSITIVE02/11/12
HTXAppendix 4C - quarterlyPRICE SENSITIVE31/10/12
HTXUS Patent Granted to HealthLinx for AGR2 BiomarkerPRICE SENSITIVE03/09/12
HTXAppendix 4E and Annual Report 2012PRICE SENSITIVE31/08/12
HTXSale of IP provides Presence in US markets for assetsPRICE SENSITIVE03/08/12
HTXTrading HaltPRICE SENSITIVE03/08/12
HTXAppendix 4C and CommentaryPRICE SENSITIVE26/07/12
HTXOvPlex patent granted in SingaporePRICE SENSITIVE06/07/12
HTXPositive Findings in South Korean Study for OvPlexPRICE SENSITIVE27/06/12
HTXOvPlex distribution expands into IndiaPRICE SENSITIVE15/05/12
HTXAppendix 4C - quarterlyPRICE SENSITIVE19/04/12
HTXNew OvPlex Publication and New Prospective TrialPRICE SENSITIVE29/03/12
HTXPivotal KFDA Study for OvPlex Ready to CommencePRICE SENSITIVE20/03/12
HTXAppendix 4D and half year financial statements December 2011PRICE SENSITIVE28/02/12
HTXNovel biomarker that predicts clinical outcome validatedPRICE SENSITIVE15/02/12
HTXAppendix 4C - quarterlyPRICE SENSITIVE25/01/12
HTXRecruitment for OvPlex second trial to be finalised earlyPRICE SENSITIVE16/12/11
HTXConvertible Note with La Jolla Cove Investors Inc for $9mPRICE SENSITIVE08/12/11
HTXHealthLinx Intellectual Property portfolio strengthenedPRICE SENSITIVE01/12/11
HTXBinding HOA with Oryzon Genomics to distribute OvplexPRICE SENSITIVE22/11/11
HTXHealthLinx CEO to resign as of 30th June 2012PRICE SENSITIVE16/11/11
HTXProstate collaboration to continue with Garvan InstitutePRICE SENSITIVE10/11/11
HTXAppendix 4C - quarterlyPRICE SENSITIVE28/10/11
HTXOvPlex patent granted in Hong KongPRICE SENSITIVE26/10/11
HTXOvPlex patent granted in Hong KongPRICE SENSITIVE26/10/11
HTXOvPlex trademark granted in ChinaPRICE SENSITIVE11/10/11
HTXSecond OvPlex trial reports increased diagnostic efficiencyPRICE SENSITIVE11/10/11
HTXINEX to expand OvPlex distribution to MalaysiaPRICE SENSITIVE07/10/11
HTXShareholder UpdatePRICE SENSITIVE27/09/11
HTXSigma Aldrich sign license agreement for IgY technologyPRICE SENSITIVE21/09/11
HTXChina partner appointed for OvPlex diagnostic studyPRICE SENSITIVE09/09/11
HTXAppendix 4E and Annual ReportPRICE SENSITIVE31/08/11
HTXAppendix 4C - quarterlyPRICE SENSITIVE28/07/11
HTXHealthLinx secures additional equity fundingPRICE SENSITIVE30/06/11
HTXHealthLinx Limited Share Purchase PlanPRICE SENSITIVE15/06/11
HTXSales of OvPlex in Singapore exceed budgetPRICE SENSITIVE14/06/11
HTXObjection to HealthLinx Patent DismissedPRICE SENSITIVE08/06/11
HTXOvPlex patent granted for AustraliaPRICE SENSITIVE03/06/11
HTXCollaboration with Garvan Institute on prostate cancerPRICE SENSITIVE17/05/11
HTXAGR2 Patent granted in EuropePRICE SENSITIVE10/05/11
HTXAppendix 4C - quarterlyPRICE SENSITIVE29/04/11
HTXLarger OvPlex study confirms 93% diagnostic efficiencyPRICE SENSITIVE08/03/11
HTXAppendix 4d and half year Dec10 accountsPRICE SENSITIVE28/02/11
HTXKey OvPlex patent grantedPRICE SENSITIVE24/02/11
HTXOvarian cancer diagnostic study delivers exceptional resultsPRICE SENSITIVE15/02/11
HTXAppendix 4C - quarterlyPRICE SENSITIVE28/01/11
HTXPart 1 of second study confirms superior efficacy of OvPlexPRICE SENSITIVE15/12/10
HTXHealthLinx signs commercial distribution deal in South KoreaPRICE SENSITIVE02/12/10
HTXExcellent early results in large OvPlex ovarian cancer studyPRICE SENSITIVE12/11/10
HTXAppendix 4C - quarterly with commentaryPRICE SENSITIVE28/10/10
HTXShareholder UpdatePRICE SENSITIVE01/10/10
HTXAgreement executed with Millipore for AGR2 researchPRICE SENSITIVE29/09/10
HTXExpansion of UK Collaborators for International OvPlex StudyPRICE SENSITIVE09/09/10
HTXOvPlex ovarian cancer diagnostic licensed for Israel marketPRICE SENSITIVE07/09/10
HTXSouth Korea OvPlex Study Commences for KFDA ApprovalsPRICE SENSITIVE01/09/10
HTXApp 4E and Annual Report 2010PRICE SENSITIVE24/08/10
HTXAppendix 4C and commentaryPRICE SENSITIVE22/07/10
HTXHealthLinx progress on prostate cancer diagnosticPRICE SENSITIVE22/06/10
HTXEthics approval obtained in South Korea for OvPlex studyPRICE SENSITIVE21/06/10
HTXHealthscope to distribute OvPlex ovarian cancer testPRICE SENSITIVE15/06/10
HTXMajor International Study Begins on OvPlex testPRICE SENSITIVE15/06/10
HTXStonebridge Securities undertake private placementPRICE SENSITIVE01/06/10
HTXAppendix 4C - quarterlyPRICE SENSITIVE29/04/10
HTXOvPlex to be launched in Singapore in JulyPRICE SENSITIVE29/04/10
HTXOvPlex sales launch in UK on 25 February 2010PRICE SENSITIVE24/02/10
HTXAppendix 4D and Half Year Accounts to December 2009PRICE SENSITIVE18/02/10
HTXSamples secured for commencement of major OvPlex studyPRICE SENSITIVE17/02/10
HTXOvPlex diagnostic clinical trial receives UK ethics approvalPRICE SENSITIVE11/02/10
HTXHealthLinx expands collaboration with Liverpool UniversityPRICE SENSITIVE22/01/10
HTXAppendix 4C - quarterlyPRICE SENSITIVE21/01/10
HTXShareholder updatePRICE SENSITIVE12/01/10
HTXSpire Healthcare agrees terms to process and market OvPlexPRICE SENSITIVE02/12/09
HTXStoneBridge Securities undertakes private placement of $1.1mPRICE SENSITIVE30/11/09
HTXTrading HaltPRICE SENSITIVE30/11/09
HTXMater Hospital ethics approval for HealthLinx OvPlex studyPRICE SENSITIVE23/11/09
HTXAppendix 4C - quarterlyPRICE SENSITIVE29/10/09
HTXHealthlinx wins $750k Victorian government grantPRICE SENSITIVE29/10/09
HTXCollaborators confirmed for next generation OvPlex studyPRICE SENSITIVE23/10/09
HTX$7.2m funding from New York based institutional investorPRICE SENSITIVE05/10/09
HTXTrading HaltPRICE SENSITIVE01/10/09
HTXMater Health Services partnered in ovarian cancer studyPRICE SENSITIVE11/09/09
HTXAppendix 4EPRICE SENSITIVE27/08/09
HTXOvPlex outperforms CA125 by more than 60%PRICE SENSITIVE04/08/09
HTXCE approval for OvPlex ovarian cancer diagnostic testPRICE SENSITIVE30/07/09
HTXAppendix 4C - quarterlyPRICE SENSITIVE27/07/09
HTXHealthLinx secures collaborators for major Ovplex studyPRICE SENSITIVE21/05/09
HTXAppendix 4C - quarterlyPRICE SENSITIVE28/04/09
HTXHealthLinx announces new $3m funding facilityPRICE SENSITIVE25/03/09
HTXAppendix 4D and Half Yearly Report and AccountsPRICE SENSITIVE25/02/09
HTXOvPlex diagnostic distribution for Singapore and SE AsiaPRICE SENSITIVE25/02/09
HTXHTX Dairy Australia study finds weight reduction compoundPRICE SENSITIVE23/02/09
HTXUK distributor to sell OvPlex in UK and IrelandPRICE SENSITIVE11/02/09
BEZ +Suspension from Official Quotation - Annual Listing Fee
25/08/14PRICE SENSITIVE
HTX Market Update and Capital Raising
13/06/14PRICE SENSITIVE
HTXSuspension from Official Quotation
30/04/13PRICE SENSITIVE
HTXMutual Termination of La Jolla Cove Investors Inc Facility
18/03/13PRICE SENSITIVE
HTXHalf Yearly Report and Accounts
28/02/13PRICE SENSITIVE
HTXAppendix 4C - quarterly
31/01/13PRICE SENSITIVE
HTXHOA with Mane Cancer Diagnostic Expires
31/12/12PRICE SENSITIVE
HTXChairman's Address to Shareholders
28/11/12PRICE SENSITIVE
HTXPrimary objective achieved in second OvPlex study
02/11/12PRICE SENSITIVE
HTXAppendix 4C - quarterly
31/10/12PRICE SENSITIVE
HTXUS Patent Granted to HealthLinx for AGR2 Biomarker
03/09/12PRICE SENSITIVE
HTXAppendix 4E and Annual Report 2012
31/08/12PRICE SENSITIVE
HTXSale of IP provides Presence in US markets for assets
03/08/12PRICE SENSITIVE
HTXTrading Halt
03/08/12PRICE SENSITIVE
HTXAppendix 4C and Commentary
26/07/12PRICE SENSITIVE
HTXOvPlex patent granted in Singapore
06/07/12PRICE SENSITIVE
HTXPositive Findings in South Korean Study for OvPlex
27/06/12PRICE SENSITIVE
HTXOvPlex distribution expands into India
15/05/12PRICE SENSITIVE
HTXAppendix 4C - quarterly
19/04/12PRICE SENSITIVE
HTXNew OvPlex Publication and New Prospective Trial
29/03/12PRICE SENSITIVE
HTXPivotal KFDA Study for OvPlex Ready to Commence
20/03/12PRICE SENSITIVE
HTXAppendix 4D and half year financial statements December 2011
28/02/12PRICE SENSITIVE
HTXNovel biomarker that predicts clinical outcome validated
15/02/12PRICE SENSITIVE
HTXAppendix 4C - quarterly
25/01/12PRICE SENSITIVE
HTXRecruitment for OvPlex second trial to be finalised early
16/12/11PRICE SENSITIVE
HTXConvertible Note with La Jolla Cove Investors Inc for $9m
08/12/11PRICE SENSITIVE
HTXHealthLinx Intellectual Property portfolio strengthened
01/12/11PRICE SENSITIVE
HTXBinding HOA with Oryzon Genomics to distribute Ovplex
22/11/11PRICE SENSITIVE
HTXHealthLinx CEO to resign as of 30th June 2012
16/11/11PRICE SENSITIVE
HTXProstate collaboration to continue with Garvan Institute
10/11/11PRICE SENSITIVE
HTXAppendix 4C - quarterly
28/10/11PRICE SENSITIVE
HTXOvPlex patent granted in Hong Kong
26/10/11PRICE SENSITIVE
HTXOvPlex patent granted in Hong Kong
26/10/11PRICE SENSITIVE
HTXOvPlex trademark granted in China
11/10/11PRICE SENSITIVE
HTXSecond OvPlex trial reports increased diagnostic efficiency
11/10/11PRICE SENSITIVE
HTXINEX to expand OvPlex distribution to Malaysia
07/10/11PRICE SENSITIVE
HTXShareholder Update
27/09/11PRICE SENSITIVE
HTXSigma Aldrich sign license agreement for IgY technology
21/09/11PRICE SENSITIVE
HTXChina partner appointed for OvPlex diagnostic study
09/09/11PRICE SENSITIVE
HTXAppendix 4E and Annual Report
31/08/11PRICE SENSITIVE
HTXAppendix 4C - quarterly
28/07/11PRICE SENSITIVE
HTXHealthLinx secures additional equity funding
30/06/11PRICE SENSITIVE
HTXHealthLinx Limited Share Purchase Plan
15/06/11PRICE SENSITIVE
HTXSales of OvPlex in Singapore exceed budget
14/06/11PRICE SENSITIVE
HTXObjection to HealthLinx Patent Dismissed
08/06/11PRICE SENSITIVE
HTXOvPlex patent granted for Australia
03/06/11PRICE SENSITIVE
HTXCollaboration with Garvan Institute on prostate cancer
17/05/11PRICE SENSITIVE
HTXAGR2 Patent granted in Europe
10/05/11PRICE SENSITIVE
HTXAppendix 4C - quarterly
29/04/11PRICE SENSITIVE
HTXLarger OvPlex study confirms 93% diagnostic efficiency
08/03/11PRICE SENSITIVE
HTXAppendix 4d and half year Dec10 accounts
28/02/11PRICE SENSITIVE
HTXKey OvPlex patent granted
24/02/11PRICE SENSITIVE
HTXOvarian cancer diagnostic study delivers exceptional results
15/02/11PRICE SENSITIVE
HTXAppendix 4C - quarterly
28/01/11PRICE SENSITIVE
HTXPart 1 of second study confirms superior efficacy of OvPlex
15/12/10PRICE SENSITIVE
HTXHealthLinx signs commercial distribution deal in South Korea
02/12/10PRICE SENSITIVE
HTXExcellent early results in large OvPlex ovarian cancer study
12/11/10PRICE SENSITIVE
HTXAppendix 4C - quarterly with commentary
28/10/10PRICE SENSITIVE
HTXShareholder Update
01/10/10PRICE SENSITIVE
HTXAgreement executed with Millipore for AGR2 research
29/09/10PRICE SENSITIVE
HTXExpansion of UK Collaborators for International OvPlex Study
09/09/10PRICE SENSITIVE
HTXOvPlex ovarian cancer diagnostic licensed for Israel market
07/09/10PRICE SENSITIVE
HTXSouth Korea OvPlex Study Commences for KFDA Approvals
01/09/10PRICE SENSITIVE
HTXApp 4E and Annual Report 2010
24/08/10PRICE SENSITIVE
HTXAppendix 4C and commentary
22/07/10PRICE SENSITIVE
HTXHealthLinx progress on prostate cancer diagnostic
22/06/10PRICE SENSITIVE
HTXEthics approval obtained in South Korea for OvPlex study
21/06/10PRICE SENSITIVE
HTXHealthscope to distribute OvPlex ovarian cancer test
15/06/10PRICE SENSITIVE
HTXMajor International Study Begins on OvPlex test
15/06/10PRICE SENSITIVE
HTXStonebridge Securities undertake private placement
01/06/10PRICE SENSITIVE
HTXAppendix 4C - quarterly
29/04/10PRICE SENSITIVE
HTXOvPlex to be launched in Singapore in July
29/04/10PRICE SENSITIVE
HTXOvPlex sales launch in UK on 25 February 2010
24/02/10PRICE SENSITIVE
HTXAppendix 4D and Half Year Accounts to December 2009
18/02/10PRICE SENSITIVE
HTXSamples secured for commencement of major OvPlex study
17/02/10PRICE SENSITIVE
HTXOvPlex diagnostic clinical trial receives UK ethics approval
11/02/10PRICE SENSITIVE
HTXHealthLinx expands collaboration with Liverpool University
22/01/10PRICE SENSITIVE
HTXAppendix 4C - quarterly
21/01/10PRICE SENSITIVE
HTXShareholder update
12/01/10PRICE SENSITIVE
HTXSpire Healthcare agrees terms to process and market OvPlex
02/12/09PRICE SENSITIVE
HTXStoneBridge Securities undertakes private placement of $1.1m
30/11/09PRICE SENSITIVE
HTXTrading Halt
30/11/09PRICE SENSITIVE
HTXMater Hospital ethics approval for HealthLinx OvPlex study
23/11/09PRICE SENSITIVE
HTXAppendix 4C - quarterly
29/10/09PRICE SENSITIVE
HTXHealthlinx wins $750k Victorian government grant
29/10/09PRICE SENSITIVE
HTXCollaborators confirmed for next generation OvPlex study
23/10/09PRICE SENSITIVE
HTX$7.2m funding from New York based institutional investor
05/10/09PRICE SENSITIVE
HTXTrading Halt
01/10/09PRICE SENSITIVE
HTXMater Health Services partnered in ovarian cancer study
11/09/09PRICE SENSITIVE
HTXAppendix 4E
27/08/09PRICE SENSITIVE
HTXOvPlex outperforms CA125 by more than 60%
04/08/09PRICE SENSITIVE
HTXCE approval for OvPlex ovarian cancer diagnostic test
30/07/09PRICE SENSITIVE
HTXAppendix 4C - quarterly
27/07/09PRICE SENSITIVE
HTXHealthLinx secures collaborators for major Ovplex study
21/05/09PRICE SENSITIVE
HTXAppendix 4C - quarterly
28/04/09PRICE SENSITIVE
HTXHealthLinx announces new $3m funding facility
25/03/09PRICE SENSITIVE
HTXAppendix 4D and Half Yearly Report and Accounts
25/02/09PRICE SENSITIVE
HTXOvPlex diagnostic distribution for Singapore and SE Asia
25/02/09PRICE SENSITIVE
HTXHTX Dairy Australia study finds weight reduction compound
23/02/09PRICE SENSITIVE
HTXUK distributor to sell OvPlex in UK and Ireland
11/02/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
Sales growth pushes Lovisa's fortunes (and shares) upwards Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.